Pharmaceutical composition for treating levodopa-induced dyskinesia or for inhibiting progression thereof
A technology for levodopa and dyskinesia, applied in drug combinations, medical preparations with non-active ingredients, medical preparations containing active ingredients, etc., can solve problems such as inability to effectively provide neuroprotection, and achieve relief of abnormal involuntary Exercise, or the effect of improving abnormal involuntary movements and reducing serious side effects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0077] The preparation of embodiment 1.SR-exenatide (PT320)
[0078] The controlled-release preparation (PT320) comprising exenatide of the present invention can be produced by double emulsification method (W / O / W method), single emulsification method (O / W method), phase separation method, and spray drying method, etc. (See Korean Patent Registration No. 10-0805208 and International Patent Publication No. PCT / US2017 / 057606 etc.). In this example, the controlled-release preparation (PT320) containing exenatide was prepared by spray drying.
[0079] 4.850 g of biodegradable polymer RG502H and 0.150 g of exenatide acetate (Polypeptide Laboratory, USA) were uniformly dissolved in 97 ml of glacial acetic acid. The prepared solution was fed into a spray dryer (SODEVA, France) equipped with an ultrasonic nozzle (Sono-tek, 120 kHz) at a flow rate of 1.5 ml / min using a piston pump while supplying dry air at 180 °C to obtain microspheres . The formed microspheres were suspended in a 0...
Embodiment 2
[0081] Example 2. Confirmation of the effect of inhibiting the progression of levodopa-induced dyskinesia.
[0082] In this example, it was confirmed whether SR-exenatide (PT320) has an effect of suppressing the progression of levodopa-induced dyskinesia.
Embodiment 2-1
[0083] Example 2-1. Administration route and dosage of SR-Exenatide (PT320) and L-DOPA
[0084] The regimen of PT320 and L-DOPA drug therapy is shown in figure 1 middle. According to this protocol, 6-OHDA was first injected into the right medial forebrain bundle at 0.25 μl / min for 10 minutes to induce injury, and then treated with L-DOPA or L-DOPA+PT320 for 22 days.
[0085] L-DOPA was dissolved in saline together with benzazide (15 mg / kg) and administered by intraperitoneal injection (ip) at 6 mg / kg / day while once a week (total 3 times) in L - PT320 (100 mg / kg, containing 2 mg / kg exenatide) was administered by subcutaneous injection (sc) 1 hour before DOPA administration in order to confirm the efficacy of inhibiting the progression of levodopa-induced dyskinesias according to drug treatment.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More